日本のバイオシミラー市場レポート分子別(インフリキシマブ、インスリングラルギン、エポエチンアルファ、エタネルセプト、フィルグラスチム、ソマトロピン、リツキシマブ、フォリトロピンアルファ、アダリムマブ、ペグフィルグラスチム、トラスツズマブ、ベバシズマブ、その他)、適応症(自己免疫疾患、血液疾患、糖尿病、がん、成長不全、女性不妊症、その他)、製造タイプ(自社製造、受託製造)、地域 2025-2033

日本のバイオシミラー市場レポート分子別(インフリキシマブ、インスリングラルギン、エポエチンアルファ、エタネルセプト、フィルグラスチム、ソマトロピン、リツキシマブ、フォリトロピンアルファ、アダリムマブ、ペグフィルグラスチム、トラスツズマブ、ベバシズマブ、その他)、適応症(自己免疫疾患、血液疾患、糖尿病、がん、成長不全、女性不妊症、その他)、製造タイプ(自社製造、受託製造)、地域 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A29207

Language of the Report – English

ただし、追加料金で日本語のレポートが入手できる場合もある。

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Japan Biosimilar Market - Introduction

    4.1    Overview
    4.2    Market Dynamics
    4.3    Industry Trends
    4.4    Competitive Intelligence
5   Japan Biosimilar Market Landscape
    5.1    Historical and Current Market Trends (2019-2024)
    5.2    Market Forecast (​2025-2033)
6   Japan Biosimilar Market - Breakup by Molecule 
    6.1    Infliximab
        6.1.1 Overview
        6.1.2 Historical and Current Market Trends (2019-2024)
        6.1.3 Market Forecast (​2025-2033)
    6.2    Insulin Glargine
        6.2.1 Overview
        6.2.2 Historical and Current Market Trends (2019-2024)
        6.2.3 Market Forecast (​2025-2033)
    6.3    Epoetin Alfa
        6.3.1 Overview
        6.3.2 Historical and Current Market Trends (2019-2024)
        6.3.3 Market Forecast (​2025-2033)
    6.4    Etanercept
        6.4.1 Overview
        6.4.2 Historical and Current Market Trends (2019-2024)
        6.4.3 Market Forecast (​2025-2033)
    6.5    Filgrastim
        6.5.1 Overview
        6.5.2 Historical and Current Market Trends (2019-2024)
        6.5.3 Market Forecast (​2025-2033)
    6.6    Somatropin
        6.6.1 Overview
        6.6.2 Historical and Current Market Trends (2019-2024)
        6.6.3 Market Forecast (​2025-2033)
    6.7    Rituximab
        6.7.1 Overview
        6.7.2 Historical and Current Market Trends (2019-2024)
        6.7.3 Market Forecast (​2025-2033)
    6.8    Follitropin Alfa
        6.8.1 Overview
        6.8.2 Historical and Current Market Trends (2019-2024)
        6.8.3 Market Forecast (​2025-2033)
    6.9    Adalimumab
        6.9.1 Overview
        6.9.2 Historical and Current Market Trends (2019-2024)
        6.9.3 Market Forecast (​2025-2033)
    6.10    Pegfilgrastim
        6.10.1 Overview
        6.10.2 Historical and Current Market Trends (2019-2024)
        6.10.3 Market Forecast (​2025-2033)
    6.11    Trastuzumab
        6.11.1 Overview
        6.11.2 Historical and Current Market Trends (2019-2024)
        6.11.3 Market Forecast (​2025-2033)
    6.12    Bevacizumab
        6.12.1 Overview
        6.12.2 Historical and Current Market Trends (2019-2024)
        6.12.3 Market Forecast (​2025-2033)
    6.13    Others
        6.13.1 Historical and Current Market Trends (2019-2024)
        6.13.2 Market Forecast (​2025-2033)
7   Japan Biosimilar Market - Breakup by Indication 
    7.1    Auto-Immune Diseases
        7.1.1 Overview
        7.1.2 Historical and Current Market Trends (2019-2024)
        7.1.3 Market Forecast (​2025-2033)
    7.2    Blood Disorder
        7.2.1 Overview
        7.2.2 Historical and Current Market Trends (2019-2024)
        7.2.3 Market Forecast (​2025-2033)
    7.3    Diabetes
        7.3.1 Overview
        7.3.2 Historical and Current Market Trends (2019-2024)
        7.3.3 Market Forecast (​2025-2033)
    7.4    Oncology
        7.4.1 Overview
        7.4.2 Historical and Current Market Trends (2019-2024)
        7.4.3 Market Forecast (​2025-2033)
    7.5    Growth Deficiency
        7.5.1 Overview
        7.5.2 Historical and Current Market Trends (2019-2024)
        7.5.3 Market Forecast (​2025-2033)
    7.6    Female Infertility
        7.6.1 Overview
        7.6.2 Historical and Current Market Trends (2019-2024)
        7.6.3 Market Forecast (​2025-2033)
    7.7    Others
        7.7.1 Historical and Current Market Trends (2019-2024)
        7.7.2 Market Forecast (​2025-2033)
8   Japan Biosimilar Market - Breakup by Manufacturing Type
    8.1    In-House Manufacturing
        8.1.1 Overview
        8.1.2 Historical and Current Market Trends (2019-2024)
        8.1.3 Market Forecast (​2025-2033)
    8.2    Contract Manufacturing
        8.2.1 Overview
        8.2.2 Historical and Current Market Trends (2019-2024)
        8.2.3 Market Forecast (​2025-2033)
9   Japan Biosimilar Market – Breakup by Region
    9.1    Kanto Region
        9.1.1 Overview
        9.1.2 Historical and Current Market Trends (2019-2024)
        9.1.3 Market Breakup by Molecule
        9.1.4 Market Breakup by Indication
        9.1.5 Market Breakup by Manufacturing Type
        9.1.6 Key Players
        9.1.7 Market Forecast (​2025-2033)
    9.2    Kansai/Kinki Region
        9.2.1 Overview
        9.2.2 Historical and Current Market Trends (2019-2024)
        9.2.3 Market Breakup by Molecule
        9.2.4 Market Breakup by Indication
        9.2.5 Market Breakup by Manufacturing Type
        9.2.6 Key Players
        9.2.7 Market Forecast (​2025-2033)
    9.3    Central/ Chubu Region
        9.3.1 Overview
        9.3.2 Historical and Current Market Trends (2019-2024)
        9.3.3 Market Breakup by Molecule
        9.3.4 Market Breakup by Indication
        9.3.5 Market Breakup by Manufacturing Type
        9.3.6 Key Players
        9.3.7 Market Forecast (​2025-2033)
    9.4    Kyushu-Okinawa Region
        9.4.1 Overview
        9.4.2 Historical and Current Market Trends (2019-2024)
        9.4.3 Market Breakup by Molecule
        9.4.4 Market Breakup by Indication
        9.4.5 Market Breakup by Manufacturing Type
        9.4.6 Key Players
        9.4.7 Market Forecast (​2025-2033)
    9.5    Tohoku Region
        9.5.1 Overview
        9.5.2 Historical and Current Market Trends (2019-2024)
        9.5.3 Market Breakup by Molecule
        9.5.4 Market Breakup by Indication
        9.5.5 Market Breakup by Manufacturing Type
        9.5.6 Key Players
        9.5.7 Market Forecast (​2025-2033)
    9.6    Chugoku Region
        9.6.1 Overview
        9.6.2 Historical and Current Market Trends (2019-2024)
        9.6.3 Market Breakup by Molecule
        9.6.4 Market Breakup by Indication
        9.6.5 Market Breakup by Manufacturing Type
        9.6.6 Key Players
        9.6.7 Market Forecast (​2025-2033)
    9.7    Hokkaido Region
        9.7.1 Overview
        9.7.2 Historical and Current Market Trends (2019-2024)
        9.7.3 Market Breakup by Molecule
        9.7.4 Market Breakup by Indication
        9.7.5 Market Breakup by Manufacturing Type
        9.7.6 Key Players
        9.7.7 Market Forecast (​2025-2033)
    9.8    Shikoku Region
        9.8.1 Overview
        9.8.2 Historical and Current Market Trends (2019-2024)
        9.8.3 Market Breakup by Molecule
        9.8.4 Market Breakup by Indication
        9.8.5 Market Breakup by Manufacturing Type
        9.8.6 Key Players
        9.8.7 Market Forecast (​2025-2033)
10  Japan Biosimilar Market – Competitive Landscape 
    10.1    Overview
    10.2    Market Structure 
    10.3    Market Player Positioning 
    10.4    Top Winning Strategies 
    10.5    Competitive Dashboard 
    10.6    Company Evaluation Quadrant 
11  Profiles of Key Players
    11.1    Company A
        11.1.1 Business Overview
        11.1.2 Product Portfolio
        11.1.3 Business Strategies
        11.1.4 SWOT Analysis
        11.1.5 Major News and Events
    11.2    Company B 
        11.2.1 Business Overview
        11.2.2 Product Portfolio
        11.2.3 Business Strategies
        11.2.4 SWOT Analysis
        11.2.5 Major News and Events
    11.3    Company C 
        11.3.1 Business Overview
        11.3.2 Product Portfolio
        11.3.3 Business Strategies
        11.3.4 SWOT Analysis
        11.3.5 Major News and Events
    11.4    Company D  
        11.4.1 Business Overview
        11.4.2 Product Portfolio
        11.4.3 Business Strategies
        11.4.4 SWOT Analysis
        11.4.5 Major News and Events
    11.5    Company E 
        11.5.1 Business Overview
        11.5.2 Product Portfolio
        11.5.3 Business Strategies
        11.5.4 SWOT Analysis
        11.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.
 
12  Japan Biosimilar Market - Industry Analysis

    12.1    Drivers, Restraints, and Opportunities
        12.1.1 Overview
        12.1.2 Drivers
        12.1.3 Restraints
        12.1.4 Opportunities
    12.2   Porters Five Forces Analysis
        12.2.1 Overview
        12.2.2 Bargaining Power of Buyers
        12.2.3 Bargaining Power of Suppliers
        12.2.4 Degree of Competition
        12.2.5 Threat of New Entrants
        12.2.6 Threat of Substitutes
    12.3    Value Chain Analysis
13  Appendix

日本のバイオシミラー市場レポート分子別(インフリキシマブ、インスリングラルギン、エポエチンアルファ、エタネルセプト、フィルグラスチム、ソマトロピン、リツキシマブ、フォリトロピンアルファ、アダリムマブ、ペグフィルグラスチム、トラスツズマブ、ベバシズマブ、その他)、適応症(自己免疫疾患、血液疾患、糖尿病、がん、成長不全、女性不妊症、その他)、製造タイプ(自社製造、受託製造)、地域 2025-2033
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials